Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma.
Foxp3
cluster of differentiation 276
cytokine
renal cell carcinoma
tumor-infiltrating lymphocyte
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
19
10
2018
accepted:
14
02
2019
entrez:
2
4
2019
pubmed:
2
4
2019
medline:
2
4
2019
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) is an immunogenic tumor and pathological specimen generally contain large quantities of tumor-infiltrating lymphocytes (TILs). Numerous cell types and cytokines could affect the immune escape mechanism of tumor cells. The aim of the present study was to investigate the prognostic impact of TILs and the associated circulating cytokines on localized clear cell RCC following radical nephrectomy. A total of 87 patients who had undergone radical nephrectomy and were pathologically diagnosed with localized clear cell RCC were included. The present study evaluated the profile of TILs with immunohistochemical analysis of tumor specimens using a panel of antibodies [cluster of differentiation (CD)-4, CD8, CD80, CD86, CD276, and Forkhead box p3 (Foxp3)]. Counts of each TIL were compared with clinicopathological variables. Based on the results of immunohistochemical analyses, putative cytokines, including interleukin (IL)-6, IL-10, IL-17, interferon-γ, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β, were selected, and their levels in preoperative serum were measured by ELISA. The levels were compared with TIL counts in tumor specimens. High counts of the CD276
Identifiants
pubmed: 30930997
doi: 10.3892/ol.2019.10057
pii: OL-0-0-10057
pmc: PMC6425371
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4004-4010Références
Clin Cancer Res. 1999 May;5(5):1219-29
pubmed: 10353760
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
J Urol. 2002 Dec;168(6):2395-400
pubmed: 12441925
Br J Cancer. 2003 Nov 17;89(10):1906-8
pubmed: 14612901
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6360S-6S
pubmed: 15448031
Nat Immunol. 2005 Apr;6(4):338-44
pubmed: 15785759
Cancer. 2005 Nov 15;104(10):2084-91
pubmed: 16208700
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Cancer. 2006 Jul 1;107(1):46-53
pubmed: 16708355
Lung Cancer. 2006 Aug;53(2):143-51
pubmed: 16782226
J Clin Oncol. 2006 Jul 1;24(19):3101-6
pubmed: 16809736
Clin Cancer Res. 2006 Sep 15;12(18):5423-34
pubmed: 17000676
Cancer. 2006 Dec 15;107(12):2866-72
pubmed: 17099880
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Gastroenterology. 2007 Jun;132(7):2328-39
pubmed: 17570208
Clin Cancer Res. 2008 Aug 15;14(16):5150-7
pubmed: 18694993
Lancet. 2009 Mar 28;373(9669):1119-32
pubmed: 19269025
Cancer Immunol Immunother. 2010 Aug;59(8):1163-71
pubmed: 20333377
BJU Int. 2011 May;107(9):1500-6
pubmed: 20735382
Crit Rev Immunol. 2010;30(5):435-47
pubmed: 21083525
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
BJU Int. 2013 Sep;112(5):686-96
pubmed: 23495770
Mol Med Rep. 2015 Feb;11(2):947-53
pubmed: 25352158
BMC Res Notes. 2016 Feb 09;9:79
pubmed: 26861149
Cancer Med. 2016 Aug;5(8):1810-20
pubmed: 27292320
Oncotarget. 2016 Oct 11;7(41):67196-67211
pubmed: 27626488
Cell Physiol Biochem. 2016;39(4):1568-80
pubmed: 27626927
Am J Surg Pathol. 1982 Oct;6(7):655-63
pubmed: 7180965